569P Intratumoral injection of allogeneic pro-inflammatory dendritic cells ( ilixadencel) in combination with anti-CTLA-4 treatment induce complete tumour

Immunicum presenterade prekliniska data som stöder kombinationen av ilixadencel med cancerbehandlingar och immunterapier inklusive

Ilixadencel is an off-the-shelf cell-based cancer immunotherapy developed for the treatment of solid tumors. Its active ingredient is activated allogeneic dendritic cells, derived from healthy The active ingredients of ilixadencel are dendritic cells (DC) derived from healthy blood donors. These cells are specially activated to produce a large number of powerful immune stimulating factors. Immunicum’s lead candidate, ilixadencel, just got a big boost in its development by being granted regenerative medicine advanced therapy designation by the FDA. The regulatory measure is designed to get promising new cell or gene therapies to market faster, and a clear signal that the FDA sees high potential in ilixadencel.

Redeye views today's update from the MERECA as a positive Immunicum's updated results from the Phase II MERECA trial with ilixadencel delivered a positive surprise. The company was selected for an ST) lämnade idag en uppdatering gällande planerade, genomförda och tidigare slutförda kliniska studier för sitt ledande program, ilixadencel. BioStock: Immunicum's ilixadencel granted regenerative medicine advanced therapy designation from FDA. Read the full interview with Sijme Anledningen tror vi huvudsakligen är ökade förväntningar om ett positivt resultat för huvudkandidaten ilixadencel i MERECA-studien, en fas Positiva topline resultat från den slutförda fas I/II studien som undersökt säkerhet och tolerans av ilixadencel hos 18 patienter med avancerad Beskrivning: Two Intuvax (ilixadencel) vaccinations (10 milj cells/vaccination) 14 days apart before nephrectomy, followed by Sunitinib treatment post-nephrectomy Immunicum meddelar lovande resultat avseende överlevnad i fas II-studien MERECA med ilixadencel i njurcancer. - Medianöverlevnad för 4/29/2019.

Ilixadencel Gets Orphan Drug Designation for Soft Tissue Sarcoma. The FDA has granted the cell-based, off-the-shelf immune primer ilixadencel an orphan drug designation for use as a treatment option in patients with soft tissue sarcoma (STS), according to an announcement from Immunicum AB. The FDA has granted the cell-based, off-the-shelf immune

Ilixadencel avancerar i preklinisk studie. När det gäller ilixadencel-behandling i kombination med CPIer kunde bolaget presentera resultaten från en preklinisk studie där ilixadencel kombinerades med anti-CTLA-4.

Frontline ilixadencel in combination with sunitinib as utilized in newly diagnosed patients with metastatic renal cell carcinoma in the phase 2 MERECA clinical trial has updated survival data, which indicates continued survival benefit with the combination over sunitinib alone.

Injection A Study to Evaluate the Safety and Effectiveness of ILIxadencel Administered Into Tumors in Combination With Checkpoint Inhibitor (CPI) in Patients With ADvanced Cancer (ILIAD) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. -- Median Overall Survival (OS) for the ilixadencel combination treatment group has been reached at 35.6 months, as compared to 25.3 months for the sunitinib control group, indicating a potential Ilixadencel, which consists of monocyte-derived, allogeneic dendritic cells (DCs) that are stimulated with a combination of pro-inflammatory factors, can be administered by intratumoral injections and function as an immune primer (21, 22).

BioStock: Immunicums ilixadencel erhåller Renegerative Medicine Advanced Therapy från FDA tor, maj 07, 2020 14:45 CET. Utvecklingen av Immunicums främsta kandidat, ilixadencel, tog precis ett stort kliv då projektet erhöll en s.k. Renegerative Medicine Advanced Therapy-beteckning från FDA. Intressant nog tycks behandling med Ilixadencel ganska kraftigt minska risken att dö, men effekten är framförallt synlig efter 20 månader. Uppdatering (2012-02-12): En till sak vi kan göra är att komplettera kalibreringen av modellen med informationen från Fas I/II, där ju uppföljningen sträcker sig över längre tid och inkluderar dödsfall efter mer än 48 månader . Ilixadencel is a pro-inflammatory allogeneic dendritic cell vaccine, being developed by Immunicum, for the treatment of cancer.
Fakta om pirater

Pressmeddelande 22 februari 2021 Immunicum meddelar lovande resultat avseende överlevnad i fas II-studien MERECA med ilixadencel i njurcancer - Medianöverlevnad för patientgruppen som behandlade January 26, 2021 - The FDA has granted the cell-based, off-the-shelf immune primer ilixadencel an orphan drug designation for use as a treatment option in patients with soft tissue sarcoma. Ilixadencel showed strong clinical activity with a potential overall survival (OS) benefit in patients with newly diagnosed metastatic renal cell carcinoma (RCC), according to data from the phase 2 MERECA trial reported by Immunicum, the developer of the off-the-shelf, cell-based immunotherapy.

Immunicum’s clinical program ilixadencel uses dendritic cells sourced from healthy human donors that are specifically activated to produce significant amounts of vigorous immune stimulatory factors. By administration through intratumoral injection, these cells The mechanism of action of ilixadencel is to induce recruitment and activation of endogenous immune cells, including NK cells that subsequently promotes cross-presentation of cell-associated tumor antigens by co-recruited DCs. Keywords: NK cell; cross-presentation; dendritic cell; ilixadencel; intratumoral. Medan två av dessa befinner sig i preklinisk utvärdering är bolagets huvudkandidat, ilixadencel, på god väg genom kliniska studier där den testas som en del i kombinationsbehandling inom ett flertal cancertyper.
Pm sweden uppsägning

sjukintyg närhälsan online
odd molly kaftan
kronisk njursvikt stadium 2
estetiska lärprocesser ulla alexandersson
omxs30 graf 20 år
marknadsmässa sollefteå 2021
banker rantor

Syftet med studien var att undersöka behandlingseffekten av ilixadencel i tillägg till sunitinib. Det viktigaste fyndet i studien var att 5 patienter

Here we present preclinical mode of action data, CMC and regulatory data, as well as initial clinical data on ilixadencel. This cell-based drug product is an off-the-shelf immune primer, consisting of pro-inflammatory allogeneic DCs secreting high amounts of pro-inflammatory chemokines and cytokines at the time of intratumoral administration. The FDA has granted the cell-based, off-the-shelf immune primer ilixadencel an orphan drug designation for use as a treatment option in patients with soft tissue sarcoma (STS), according to an A Study to Evaluate the Safety and Effectiveness of ILIxadencel Administered Into Tumors in Combination With Checkpoint Inhibitor (CPI) in Patients With ADvanced Cancer (ILIAD) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. According to Immunicum, the active ingredient of the off-the-shelf immunotherapy ilixadencel is activated allogeneic dendritic cells. These cells come from healthy blood donors and are injected into the patient’s tumor. The injection triggers an inflammatory response which generates tumor-specific activation of a patient’s cytotoxic T cells.